BSECompany Update4d ago · 8 Aug 2026, 03:47 pm

Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.

Ishita Drugs & Industries Ltd · 524400

✦ AI SummaryMgmt Change

Ishita Drugs & Industries Ltd has announced the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director of the Company post attaining the age of 75 years. The Board of Directors also approved the Unaudited Financial Results for the quarter ended 30th June, 2026, and accepted the revised remuneration proposal of Mr. Sumit Agrawal, Chief Financial Officer of the Company. The meeting also discussed the upgradation project of the manufacturing facility for compliance with Revised Schedule M.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Ishita Drugs & Industries Ltd - 524400 - Announcement under Regulation 30 (LODR)-Change in Management

Attachments (1)

📄

d07d13d4-bcde-425a-bdf5-52647ca3ce38.pdf

pdf

Download →
View document text
ISHITA DRUGS & INDUSTRIES LTD. Corp. Off.: 401, 3rd E)ne 11. Opp. Parlmal Garden, C. G. Road, Ahmedabad-380006. I.gd. OfRce & Factory : 179/I, Vasna-Iyava, Tal. Sanand, Dist. . Ahmedabad. E-mall : ishitadru I info®ishltadruEs.com I URL : www.ishitadmues,com Phone : +91 7226995613/ 14/ 15 I +9179 4002 3839 Date: 08.08.2026 The Department of Corporate Services, BSE Limited. Floor No. 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumhai-400001. Scrip Code: 524400 Dear Sir"adam, Subiect: Outcome of Boardd Meetim! held on O8tll Auf!ust. Z026 Pursuant to the regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of lshita Drugs and Industries Limited, held its meeting today i.e. Saturday, 08th August, 2026. 1. The Board of Directors approved the Unaudited Financial Results of the Company for the quarter ended 30th )une, 2026. The Limited Review Report issued by the Statutory Auditors of the Company is enclosed herewith. 2. Based on the recommendation of Nomination and Remuneration Committee, Board of Directors have approved the re-appointment of Mrs. Abha Agrawal (DIN 01589479) as a Non-Executive Non-Independent mrector of the Company post attaining the age of 75 years, and, who retires by rotation, being eligible, offers herself for re-appointment, which is subject to the approval of the shareholders of the Company. On the basis of the disclosures received from Mrs. Abha Agrawal aplN 01589479), it is hereby confirmed that she is not debarred from holding the office of Director by virtue of any order passed by the SEBl or any other such authority. The required details pursuant to SEBI Listing regulations are annexed herewith as Annexure - I. The composition of Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations. •our 6wie drigs in the sonrice Of hrmLmdy uiofdwide . CIN No. L24231GJ1992PLC017054 D 8 a D-U-N€ Number -65JJ18-0359 lsHITA DRUGS & INDUSTRIES LTD. Corp. OW* 401, 3rd E)re 11, Opp. ParimaLI Garden. C. G. Road, Ahmedabad-380006. Reed. Office & FaLctory : 179/I. \fasna-lya`ra, Tal. Sanand, Disc. . Ahmedabad. E-mall : ishitadrugs@gmall.com I lnfo@lshltadruEs.com I URL : m^^Mishitadrugs.com Phone : +91 7226995613/ 14/ 15 I +9179 4002 3839 3. The Board considered and approved the amendment in the Notice for convening the 33rd Annual General Meeting of the Company. 4. Based on evaluation by Audit Committee and recommendation of Nomination and remuneration committee, Board of Directors accepted the revised remuneration proposal of Mr. Sumit Agrawal, Chief Financial Officer of the Company. 5. Discussed the upgradation project of manufacturing facility for compliance with Revised Schedule M. The Managing Director informed that the upgradation work is ongoing. The construction of a new block, envisaged to accommodate the new warehouse area, has been completed and civil work is going on for the extension of the existing buildings. Till date, the Company has spent nearly Rs. 435 lakh towards renovation of existing buildings and construction of new blocks. Further, capital contracts / orders of about Rs. 565 lakh have been issued for various utilities and equipments. The Company is also actively negotiating with different banks to raise funds for financing this upgradation project. The meeting was commenced at 02:30 p.in, and concluded at 03:25 p,in. Please take the above details on your records. Thanki ng You. For, Ishita Drugs and Industries Limited |agdish Agrawal Managing Director DIN: 01031687 •our 6asie drigs in ch& schce Of hunandy .i}or[6wid¢ CIN No. L24231GJ1992PLC017054 D a a D-U-N€ Number 65rdl8-0359 a`J;m#,I,J& J3Lmf i ::i|£#:-:-L§:so:mp,ex, s s 0 c I 11 I Q, S 2nd Floor, Soni nl Chawl, Cross Road, Odhav, Ahmedabad.382415 Date : ce/08/2026 TheBoardofDirectors, ` :shin Drugs & ?ndustries limited, AJ-abad. llMITED REVIE\^/ REPOF`T W'e liave re.newed the a{comparning Of unaudfted financ]a I resu.ts Of lsHrTA mues AND INOuST"ES LJMITED for the period 01 Apr 2026 to 30 JLln 20Z6. (The Statelr±ot) being submitted by the Company I)ursirant to the requirement of Regulation 33 of SE8l (Usting of'CX)Tigation and Disc!esure Requiremerrts) F`egulation, 2015 read with SEBI Circular No. CIR/CID/FAC/62/2016 dated 5" July, 2016. Tliis statemem is the responsibilfty of the Company's Management and has been approved fry the Board Of Directors. Our resporsibll fry is to issue a report on these finanoal statements based on our review. We condLicted our ra'iei^i [n actardaite widi the Standard on Re.,lew Engapemerit (SRE) 2410. Review of lf.teTinfinar[ialinformaGonperfomedbythelndepei.dentauditDrOftl`eeTkityissLiedb`/thelnstitLrte of Ct.altered Acaoiimalts Of India. This Standard requires that we plan and perfom` the review to obtain moderate assurance aLs to whether the final.cia! statements are free of matenal misstatement. A review is !`imited primarily to inqurries Of conpant' personnel and ama:vtical prceedures appr led to finandal data and thus provide less assun)nce tlian an audit. We hanfe riot perfomred an audit and according:y, we do rot express an aud`rt opinion. Based on our re\dew. col`d`icted as above, nothing has come to oiir attention that causes us to be! ieve that the accompanying statement Of unaudited firrancial resu:ts prepared in arccordance with Indian ac{ourting Standards presc)ibe under section 133 Of companies Act,2013 read `vith Te!e`ont rules issued there under and ancther iecognized accounting practices and policies lias not disclosed the infomation required to be dtsc;osed in terms of Regu*tion 33 of SEBl (listhg Ch Obhgat]co and Disc`osure Requirements) Regulatlon, 201S read \vith SEBi Circular No. ClfycFD/FAC/62/20L6 dated S.`. July, 2016 iiicluding the mamer in `vhldi it is to be d.Lsc.osed, or that it contains any mateTtal misstatemert. for and or` behatf Of ]F"N sl+^I+ a ^ssoa^TEs Chartered Accountartts CA Ma`/anl( Sanchcti M NO. :i7oes3 0tate: 08/es/2026 Place: AIUTtedabad UE)I N: 26170863 Hum IOX6931 (`,}i9ri|llJ Btl` rills ,\!(diiii [`/ i),`")# Aanqan NetG, I,``f.i,:,`r r !}izwii;lI Uf lii:+! 5U4, }7alladiui`i Biis!r)t;s` I(ijl) A(wt{ F'd{"tiltioHs, Opp 4D Mall , PVF` Cinema, Vi§@I Gantlhlnaflar Highway, Ahme{lab8d 382424 L'\ llJl„7.Il,L,,)„ ll ( 11 „lljl))'l, ;)::tL„:,``1/``t Ea c;iii`fiy#iilstiii{:lioli(te{`ifiia.I I:riii\ ; , , f', ( I i I I I i 11 i( ,! / `i' LL'i= a==a t;83IaILL 3I.gXLL'E XEE=6 a'E8I05 #Iit=®I5 u,E8aE0ti.;u V,I0ga,CLaE€=ESce i;EIE€09®=t53 0®=tTC1!%a,aJ=E!ICL a'CaCLX|LJtiC=®a)iiiEtLJ =05iE 9!Ia'CLXLL'I0S'EaEaaIaI:0a;CLac`a%u£a.a ®tI+Iij!eI09¥a-IJ±;u,`%aa|J0Iu\ILJ-i58eI9IIiI®5 §f=0Ii ?IidX=£ a,IBIa80iD€Ia¥§C=aJBEJauu0::i:i 0iIj I=IiaU|i=8I8±ii U,8?aE:IE=?i€3a'€EEi§ 8ae2aIU1£ii§a,0iCEI0E< =IIgI £s`af=IEIE3¥E¥§€IdIIIti== mBii =3.I at-. ®Ia. ®I=3==5i i=+in i.,\,.- =nan ®00N cO®ru,On 3aln C>ac)` Caac) inc5* 0t-t< :II:3 St==i S:c1r1 3c5IV, ac)' nC)Sn 0qI,in r1r,r, inOaa® C>Lr'00 aC>a i=II, 5V)I ®aV\C) t,ininN 00~o'r,r' 8c5# 00a5® Vl,5® aac)' LnTi r,r, 0®CE:.aJa.LJJi:a 9£&f=i& jECL6aa,aCLJ|Jg ji-?EflEIa E-toIIJE19Ja CLE-u,aoIIaIJJ0u,0Ea I0tE;.aI.Illi?EE C|j!-aIIaLJJuu,0a) to0=g=8i;J±£ ECie5i±=Eri;in§ jECL6£0IU).aIt,IJJaJIg 0J£Ig6®JS8J= a£g£8'E#i:a :a,#I0iiEa'E£II£a 00ceaI3a,1,i#?9I ej!JE,IiE5€i J3'Ei8=0Iu).aICrIJJi;0JS8E! 29!a'CEE.9aI£tDI0I=:8aa: iIa'aEiEaitE9£=Ii& €=at5=0I:8®aj=IJDt:a#`0a¥a. V,8ia'aI=C€59®5;igiE ?9ItagEE0YIaI€0=j=IJ2I:03`0Ef 9J±J3£i3®€Ea'i?Ig:i V,Ia£a'CLacOIIC:I8E9=0Iu,a' E=.9=a0eoCJII8E€90J=V'9. IaEaaIa'IIC8|JE€±aJ=ODa'a.£-aIE0IJJ1'g Ia=aa|J0IIIa3aE€±®Ia£-aII0LLlEIa £9at5±a,I:0I90aj=IJ2%Ea'a.a'€€a'EauI9IaI=CLE8 I.9=a'aai;I1=E81BC=atroIIEI8E€9aJ=a' I0Eg0t'a,JCEa#|J1C=0toIICI8E99aIa,i I0£Eg-ii .aIacOIIJ2|Je!II?®?II9I:iDI®£aa#ai;?-Ea-titff ?Ftii;I0E8I9®C0£91E8a,J=6 BEa'€Ea!I€E§! =0It:9ai5=a'Iaa'I80a€Iai:a%&®Iea'E8C:i.iaEc:i Xa9:Caga.ai;JII84E€a£-¥CL OnIaIE0BICEa#0t5aI®1XLJJX£ Xjg£au,Iagaaea,IIIaDE€j!-ECLa:Z 8a.On t-t`c; I [Showing first 8,000 characters — download PDF for full document]